Skip to content

Newsroom

type
year
Illustration image.png

125,000 Orion Corporation A shares converted into B shares

10/7/2026 Stock exchange release
Orion Espoo.jpg

Orion Pharma invests in strengthening pharmaceutical manufacturing across four Finland locations

10/6/2026 Orion Pharma and Society
Illustration image.png

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

10/6/2026 Press release
Illustration image.png

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

10/5/2026 Press release
Illustration image.png

Orion Corporation completed share acquisitions

9/30/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 40, 2026

9/30/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 39, 2026

9/25/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 38, 2026

9/18/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 37, 2026

9/11/2026 Stock exchange release
Illustration image.png

Orion Corporation: Acquisition of own shares during week 36, 2026

9/4/2026 Stock exchange release
Prostate-Cancer-Researchers-Hero-1500x844.jpg

“This is a researcher's dream” – How a prostate cancer medicine was discovered at Orion Pharma

9/4/2026 Science and Partnering
Illustration image.png

102,000 Orion Corporation A shares converted into B shares

9/4/2026 Stock exchange release
Illustration image.png

Orion Corporation to commence acquisition of own shares for its share-based incentive plans

8/27/2026 Stock exchange release
Orion Pharma_Engineers_group image_1500x844.jpg

A technical career at Orion Pharma – Technical expertise is needed at every stage of medicine manufacturing

8/10/2026 We are Orion Pharma
Illustration image.png

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

8/10/2026 Stock exchange release
Illustration image.png

Orion Group Half-Year Financial Report January–June 2026

7/17/2026 Stock exchange release
Illustration image.png

Orion Corporation’s financial reporting and Annual General Meeting in 2027

7/17/2026 Stock exchange release
Illustration image.png

45,611 Orion Corporation A shares converted into B shares

7/15/2026 Stock exchange release